sofosbuvir/velpatasvir vs sulfasalazine
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of sofosbuvir/velpatasvir and sulfasalazine. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
moderate Known Drug Interaction
Coadministration of VOSEVI with BCRP substrates (e.g., methotrexate, mitoxantrone, imatinib, irinotecan, lapatinib, rosuvastatin, sulfasalazine, topotecan) is not recommended [see Clinical Pharmacology (12.3) ].
Epclusa
Azulfidine
Vosevi is a drug that combines three medicines into one tablet. It is used to treat hepatitis C in adults who have already tried other treatments.
Sulfasalazine is a drug that reduces inflammation in the body. It is used to treat ulcerative colitis.
Vosevi treats chronic hepatitis C (HCV) infection in adults. It is for those without cirrhosis or with compensated cirrhosis (Child-Pugh A). You can use it if you have genotype 1, 2, 3, 4, 5, or 6 HCV. You must have already been treated with a hepatitis C medicine containing an NS5A inhibitor, or sofosbuvir without an NS5A inhibitor (for genotypes 1a or 3).
Sulfasalazine treats ulcerative colitis, a condition that causes inflammation and sores in the lining of the large intestine. It can help with mild to moderate ulcerative colitis. It can also be used with other treatments for severe ulcerative colitis. This medicine can also help keep ulcerative colitis from coming back.
Vosevi contains sofosbuvir, velpatasvir, and voxilaprevir. Sofosbuvir blocks a protein called NS5B polymerase that the hepatitis C virus needs to multiply. Velpatasvir blocks the NS5A protein, and voxilaprevir blocks the NS3/4A protease protein, both of which the virus also needs.
Sulfasalazine is an anti-inflammatory drug. It works by reducing inflammation in the colon. The exact way it does this is not fully known.
- • Headache
- • Fatigue (feeling tired)
- • Diarrhea
- • Nausea (feeling sick to your stomach)
- • Loss of appetite
- • Headache
- • Nausea
- • Vomiting
- • Stomach upset
- Feeling tired 2,307
- Hepatitis C infection 1,734
- Headache 1,639
- Feeling sick to your stomach 1,386
- Low red blood cell count 1,185
- Rheumatoid Arthritis 19,190
- Pain 15,658
- Arthralgia 13,161
- Fatigue 13,017
- Joint Swelling 12,481
Vosevi can cause Hepatitis B to become active again if you have had it in the past. This can cause serious liver problems, including liver failure and death. Before starting Vosevi, your doctor will test you for Hepatitis B. They will also monitor you during and after treatment.
You should not take this medicine if you have a blockage in your intestines or urinary tract. You should not take this medicine if you have porphyria, as it could cause an attack. You should not take this medicine if you are allergic to sulfasalazine, its ingredients, sulfonamides, or salicylates.
It is not known if Vosevi can harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is also not known if Vosevi passes into breast milk, so discuss this with your doctor if you are breastfeeding.
Tell your doctor if you are pregnant or plan to become pregnant. It is not known if Sulfasalazine will harm your unborn baby. Talk to your doctor about the risks and benefits of taking this medicine while breastfeeding.
Also Compare, Nearby Drugs
Compare sulfasalazine with
How to Read This sofosbuvir/velpatasvir vs sulfasalazine Comparison
sofosbuvir/velpatasvir is classified in the NS5B/NS5A Inhibitor (HCV) drug class, while sulfasalazine sits within the Disease-Modifying Antirheumatic Drug (DMARD) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, sofosbuvir/velpatasvir has 8,251 submissions while sulfasalazine has 73,507. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known moderate interaction flagged in FDA labeling, attributed to this medicine interferes with a protein that transports sulfasalazine, which could cause the levels of sulfasalazine in your body to rise.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for sofosbuvir/velpatasvir or sulfasalazine.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.